ArticleInternational journal of women's health2026
Expression of CXCL10 and CXCL16 in Triple-Negative Breast Cancer and Their Association with Immunotherapy Efficacy and Prognosis.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype with limited therapeutic options. This study investigated the expression patterns of chemokines CXCL10 and CXCL16 in TNBC and their association with immunotherapy response and clinical outcomes. Methods: We retrospectively analyzed 128 TNBC patients treated at our institution between 2019-2023. CXCL10 and CXCL16 expressions were assessed by immunohistochemistry. Sixty-eight patients received immune checkpoint inhibitor (ICI)-based therapy. The primary endpoints were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: High CXCL10 expression (≥50% positive cells) was observed in 72 patients (56.25%), while high CXCL16 expression was found in 65 patients (50.78%). In the immunotherapy cohort, patients with high CXCL10 expression demonstrated significantly higher ORR (44.44% vs 18.75%, p=0.024) and longer median PFS (8.62 vs 4.35 months, HR=0.467, 95% CI: 0.268-0.814, p=0.007). Combined high expression of both chemokines showed the most favorable outcomes, with ORR of 52.63% and median PFS of 10.84 months. Multivariate Cox regression confirmed CXCL10 (HR=0.512, p=0.008) and CXCL16 (HR=0.623, p=0.032) as independent prognostic factors for PFS. Conclusion: CXCL10 and CXCL16 expression levels are associated with improved immunotherapy response and favorable prognosis in TNBC and may serve as candidate predictive biomarkers. Combined assessment of both chemokines may optimize patient selection for ICI-based therapy. Prospective validation in larger cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.